[{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"b4947302-8201-4385-90e7-1045ddc21de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220022","created_at":"2021-01-18T15:53:27.752Z","updated_at":"2025-02-25T17:29:32.862Z","phase":"Phase 1","brief_title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","source_id_and_acronym":"NCT03220022","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 06/20/2025","study_completion_date":" 06/20/2025","last_update_posted":"2025-01-30"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"1a45b9a8-1ce6-44b5-95d7-d7e7942de13d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00063999","created_at":"2021-01-18T00:08:57.515Z","updated_at":"2024-07-02T16:36:22.771Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00063999","lead_sponsor":"GOG Foundation","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 1381","initiation":"Initiation: 08/25/2003","start_date":" 08/25/2003","primary_txt":" Primary completion: 06/29/2013","primary_completion_date":" 06/29/2013","study_txt":" Completion: 01/05/2021","study_completion_date":" 01/05/2021","last_update_posted":"2021-10-19"}]